Middle East And Africa Liquid Biopsy Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
|
 TCAC |
% |
| Principaux acteurs du marché |
>Marché de la biopsie liquide au Moyen-Orient et en Afrique, par produit (instruments, consommables et accessoires, services et logiciels), type de biofabricant ( cellules tumorales circulantes (CTCS) , ADN acellulaire circulant (CFDNA), ARN acellulaire, vésicules extracellulaires, exosomes et autres), type d'échantillon (basé sur un échantillon de sang, basé sur un échantillon d'urine, basé sur un échantillon de salive et d'autres liquides tissulaires, et autres), type d'analyse (moléculaire, protéomique et histologie/imagerie), type d'application (applications cancéreuses et applications non cancéreuses), application clinique (dépistage de routine, bilan des patients, sélection de thérapie, surveillance du traitement, surveillance des récidives et autres), technologie (analyse parallèle multigénique et analyse monogénique), utilisateur final (hôpitaux, laboratoires de référence, centres de diagnostic, centres de recherche et instituts universitaires, et autres), canal de distribution (appel d'offres direct, distributeur tiers et autres) - Industrie Tendances et prévisions jusqu'en 2030.
Analyse et perspectives du marché de la biopsie liquide au Moyen-Orient et en Afrique
La prise de conscience croissante des technologies de diagnostic avancées au Moyen-Orient et en Afrique a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'amélioration des processus et des techniques contribue également à la demande croissante de biopsie liquide.
Le marché de la biopsie liquide au Moyen-Orient et en Afrique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans l'activité de développement pour lancer de nouveaux services sur le marché. Le développement croissant dans le domaine des techniques de soins de santé avancées stimule encore davantage la croissance du marché.
Cependant, des difficultés telles que le manque de protocoles standardisés et le manque de professionnels qualifiés pourraient entraver la croissance du marché de la biopsie liquide au Moyen-Orient et en Afrique au cours de la période de prévision.
Data Bridge Market Research analyse que le marché de la biopsie liquide au Moyen-Orient et en Afrique connaîtra un TCAC de 11,7 % au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions, volumes en unités, prix en USD |
|
Segments couverts |
Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) |
|
Countries Covered |
Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and the rest of the Middle East and Africa |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, Bio-Rad Laboratories, Inc. , Natera, Inc., CARDIFF ONCOLOGY, INC., and Sysmex Inostics Inc. among others |
Market Definition
A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient's blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases.
Middle East and Africa Liquid Biopsy Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below
Drivers
- Growing demand for non-invasive liquid biopsy technique
Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles among others, present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years, as described in the review, thus providing greater details about tumor characteristics such as mutations, tumor staging, tumor progression, heterogeneity, and gene and clonal evolution, among others. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Non-invasive cancer diagnostics offer a safer and more patient-friendly approach, resulting in a growing demand for these methods.
- Advancements in precision medicine due to liquid biopsy
Precision medical oncology in the clinical management of cancer may be achieved through the diagnostic platform called "liquid biopsy" (LB). The LB was recognized as a powerful real-time approach for the molecular monitoring of this dynamic cancer disease. This method utilizes the detection of Biomakers in blood for prognostic and predictive purposes by non-invasive means, which in the near future will represent a change in the paradigm of molecular biology understanding and the heterogeneity of tumors. Advancements in precision medicine, fueled by the use of liquid biopsy techniques, have contributed significantly to the growing demand for non-invasive cancer diagnostics. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), or exosomes in blood or other body fluids, provide valuable information about the genetic makeup of tumors, enabling precision medicine approaches in cancer care.
Opportunity
- Integration of Artificial Intelligence (AI) and machine learning
Liquid biopsy-based approaches offer many new opportunities to measure molecular Biomakers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.
Thus, the integration of AI and machine learning is expected to act as an opportunity for the growth of the market.
- Increasing reimbursements and government support for liquid biopsy
The adoption of liquid biopsy has been significantly influenced by government backing. Governments throughout the world have put legislation in place to encourage the adoption of liquid biopsy because they understand how it may enhance patient care, lower healthcare costs, and advance precision medicine. Incorporating liquid biopsy into national cancer screening programs or treatment recommendations is only one example of how this might be done. Other examples include financing for research and development of liquid biopsy technologies and backing clinical trials and studies to produce evidence on their therapeutic efficacy. Such government assistance has aided in boosting liquid biopsy test knowledge, adoption, and reimbursement coverage.
Thus, increasing reimbursements and government support for liquid biopsy is expected to act as an opportunity for the market's growth.
Restraint/Challenge
- High cost of liquid biopsy tests
The liquid biopsy is severely constrained by the high cost. While liquid biopsy tests show promise for non-invasive illness detection and monitoring, including cancer, there are cost-related obstacles that may prevent their widespread use.
The necessity for specialized tools and technologies is one of the biggest economic obstacles. Costly tools, including digital PCR machines, NGS platforms, and automated sample processing systems, are frequently needed for liquid biopsy studies. Smaller healthcare facilities with tighter budgets may find it difficult to afford the initial investment and ongoing maintenance costs connected with these technologies, which limits their capacity to provide liquid biopsy tests to patients.
Thus, the high cost of liquid biopsy tests is expected to restrain the market's growth.
- Lack of skilled professionals performing liquid biopsy
The demand for liquid biopsy tests is increasing due to their potential clinical utility in cancer detection, monitoring, and personalized treatment decision-making. However, there may be limited resources, including personnel, equipment, and funding, to support the implementation of liquid biopsy programs in healthcare institutions. This can result in a shortage of skilled professionals who can perform liquid biopsy tests, especially in regions or healthcare settings with limited resources.
Thus, the lack of skilled professionals performing liquid biopsies is expected to challenge the market growth.
Recent Development
- In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).
Middle East and Africa Liquid Biopsy Market Scope
The Middle East and Africa liquid biopsy market is categorized into nine notable segments which are product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel. The growth amongst these segments will help you analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Instruments
- Consumables & Accessories
- Services & Software
On the basis of product, the market is segmented into instruments, consumables & accessories, services & software.
Biomaker Type
- Circulating Tumor Cells (CTCS)
- Circulating Cell-Free DNA (CFDNA)
- Cell-Free RNA
- Exosomes
- Extracellular vesicles
- Others
On the basis of biomaker type, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), cell-free RNA, extracellular vesicles, exosomes, and others.
Sample Type
- Blood Sample-Based
- Urine Sample-Based
- Saliva & Other Tissue Fluids Sample-Based
- Others
On the basis of sample type, the market is segmented into blood sample-based, urine sample-based, saliva & other tissue fluid sample-based, and others.
Analytical Type
- Molecular
- Proteomic
- Histology/Imaging
On the basis of analytical type, the market is segmented into molecular, proteomics, and histology/imaging.
Application Type
- Cancer Applications
- Non-Cancer Applications
On the basis of application type, the market is segmented into cancer applications and non-cancer applications.
Clinical Application
- Routine Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
- Patient Work-Up
- Others
On the basis of clinical application, the market is segmented into routine screening, patient work-up, therapy selection, treatment monitoring, recurrence monitoring, and others.
Technology
- Multi-Gene-Parallel Analysis
- Single Gene Analysis
On the basis of technology, the market is segmented into multi-gene parallel analysis and single-gene analysis.
End User
- Hospitals
- Reference Laboratories
- Diagnostics Centers
- Research Centres and Academic Institutes
- Others
On the basis of end user, the market is segmented into hospitals, reference laboratories, diagnostic centers, research centers & academic institutes, and others.
Distribution Channels
- Direct Tender
- Third Party Distributor
- Others
On the basis of distribution channel, the market is segmented into direct tender, third party distributor, and others.
Middle East and Africa Liquid Biopsy Market Regional Analysis/Insights
The Middle East and Africa liquid biopsy market is analyzed, and market size insights and trends are provided based on product, biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel.
The countries covered in this market report are Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and the rest of the Middle East and Africa.
En 2023, l’Afrique du Sud devrait dominer la région du Moyen-Orient et de l’Afrique grâce aux avancées technologiques des plateformes de biopsie liquide dans le pays.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et de l'impact des tarifs nationaux et des routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché de la biopsie liquide au Moyen-Orient et en Afrique
Le paysage concurrentiel du marché de la biopsie liquide au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, l'analyse de la marque, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la biopsie liquide au Moyen-Orient et en Afrique.
Certains des principaux acteurs du marché de la biopsie liquide au Moyen-Orient et en Afrique sont F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC. et Sysmex Inostics Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS:
6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
7.2 RESTRAINTS
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS
7.2.2 LACK OF STANDARDIZED GUIDELINES
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.2.1 TEST KITS
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
8.2.1.2 DNA ISOLATION KIT
8.2.1.3 OTHERS
8.2.2 COLLECTION TUBES
8.2.2.1 50 PIECES
8.2.2.2 100 PIECES
8.2.3 ASSAYS
8.2.3.1 FLEXIBLE REAGENTS
8.2.3.2 SCALABLE REAGENTS
8.2.3.3 OTHERS
8.2.4 CONTROL KIT
8.2.5 OTHERS
8.3 INSTRUMENTS
8.3.1 ANALYZERS
8.3.2 SYSTEMS
8.3.3 OTHERS
8.4 SERVICES & SOFTWARE
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
8.4.2 DPCR ANALYSIS SOFTWARE
8.4.3 CASTPCR ANALYSIS SOFTWARE
8.4.4 OTHERS
9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
10.5 OTHERS
11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.2.1 NGS
11.2.2 PCR
11.2.3 MICROARRAY
11.2.4 PROTEOMICS
11.2.5 OTHERS
11.3 PROTEOMIC
11.3.1 NGS
11.3.2 PCR
11.3.3 MICROARRAY
11.3.4 PROTEOMICS
11.3.5 OTHERS
11.4 HISTOLOGY/IMAGING
12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.2.1 LUNG
12.2.2 BREAST
12.2.2.1 EARLY BREAST CANCER
12.2.2.2 ADVANCED BREAST CANCER
12.2.3 COLORECTAL
12.2.4 PROSTRATE
12.2.5 LIVER
12.2.6 OTHERS
12.3 NON-CANCER APPLICATIONS
12.3.1 PRENATAL DIAGNOSIS
12.3.2 PERSONALIZED IMMUNOTHERAPY
12.3.3 OTHERS
13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.4.1 EARLY-STAGE DISEASE
13.4.2 LATE-STAGE/METASTATIC DISEASE
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 MULTI-GENE-PARALLEL ANALYSIS
14.3 SINGLE GENE ANALYSIS
15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTIC CENTERS
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
15.6 OTHERS
16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 U.A.E.
17.1.4 EGYPT
17.1.5 ISRAEL
17.1.6 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GUARDANT HEALTH
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 THERMO FISHER SCIENTIFIC INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 EXACT SCIENCE CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 QIAGEN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ANGLE PLC (2022)
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BIOCEPT, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BIO-RAD LABORATORIES, INC. (2022)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 EPIC SCIENCES
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 FLUXION BIOSCIENCES INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 ILLUMINA, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 SWOT ANALYSIS
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 JOHNSON & JOHNSON PRIVATE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 MDXHEALTH
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MENARINI SILICON BIOSYSTEMS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 NATERA, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 NEOGENOMICS LABORATORIES
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 ONCOCYTE CORPORATION
19.18.1 COMPANY PROFILE
19.18.2 SERVICE PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 PATHAI
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PREDICINE
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.21 STRECK
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYSMEX INOSTICS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE
TABLE 2 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 61 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 63 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 65 MIDDLE EAST AND AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 68 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 87 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 90 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 92 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 93 SOUTH AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 96 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 97 SOUTH AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 103 SOUTH AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 SOUTH AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 105 SOUTH AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 SOUTH AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 107 SOUTH AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 SOUTH AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 SOUTH AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 110 SOUTH AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 SOUTH AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 116 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 119 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 121 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 122 SAUDI ARABIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 125 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 126 SAUDI ARABIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 128 SAUDI ARABIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 129 SAUDI ARABIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 132 SAUDI ARABIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 133 SAUDI ARABIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 134 SAUDI ARABIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 135 SAUDI ARABIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 SAUDI ARABIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 SAUDI ARABIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 SAUDI ARABIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 139 SAUDI ARABIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 SAUDI ARABIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 U.A.E. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.A.E. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.A.E. CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 U.A.E. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 145 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 148 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 151 U.A.E. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 154 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 155 U.A.E. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 U.A.E. LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.A.E. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 U.A.E. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.A.E. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.A.E. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.A.E. LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.A.E. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 163 U.A.E. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 164 U.A.E. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.A.E. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.A.E. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.A.E. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 U.A.E. LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 U.A.E. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 EGYPT LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 EGYPT CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 EGYPT CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 EGYPT LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 174 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 177 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 180 EGYPT ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 183 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 184 EGYPT SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 EGYPT LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 186 EGYPT LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 187 EGYPT LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 188 EGYPT MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 189 EGYPT PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 190 EGYPT LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 EGYPT CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 EGYPT BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 EGYPT NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 194 EGYPT LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 195 EGYPT TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 EGYPT LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 197 EGYPT LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 198 EGYPT LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 199 ISRAEL LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 ISRAEL CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 ISRAEL CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 ISRAEL LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 203 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 206 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 207 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 208 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 ISRAEL ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 213 ISRAEL SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 214 ISRAEL LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 215 ISRAEL LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 216 ISRAEL LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 217 ISRAEL MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 218 ISRAEL PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 219 ISRAEL LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 ISRAEL CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 ISRAEL BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 ISRAEL NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 223 ISRAEL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 ISRAEL TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 225 ISRAEL LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 226 ISRAEL LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 227 ISRAEL LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET
FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY
FIGURE 15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, 2022
FIGURE 16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022
FIGURE 20 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)
FIGURE 22 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022
FIGURE 24 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022
FIGURE 28 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022
FIGURE 32 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022
FIGURE 36 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022
FIGURE 40 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, 2022
FIGURE 44 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SNAPSHOT (2022)
FIGURE 52 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2022)
FIGURE 53 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)
FIGURE 56 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
